AZNCF

Shore Capital Reiterates AstraZeneca (AZNCF) Buy Recommendation

Fintel reports that on October 7, 2025, Shore Capital reiterated coverage of AstraZeneca (OTCPK:AZNCF) with a Buy recommendation.

Analyst Price Forecast Suggests 12.41% Upside

As of September 30, 2025, the average one-year price target for AstraZeneca is $179.16/share. The forecasts range from a low of $91.21 to a high of $251.13. The average price target represents an increase of 12.41% from its latest reported closing price of $159.38 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for AstraZeneca is 52,200MM, a decrease of 7.61%. The projected annual non-GAAP EPS is 9.12.

What is the Fund Sentiment?

There are 64 funds or institutions reporting positions in AstraZeneca. This is an decrease of 5 owner(s) or 7.25% in the last quarter. Average portfolio weight of all funds dedicated to AZNCF is 1.05%, an increase of 18.66%. Total shares owned by institutions decreased in the last three months by 9.01% to 16,035K shares.

What are Other Shareholders Doing?

TCIEX - TIAA-CREF International Equity Index Fund Institutional Class holds 2,580K shares representing 0.17% ownership of the company. In its prior filing, the firm reported owning 2,529K shares , representing an increase of 1.98%. The firm decreased its portfolio allocation in AZNCF by 0.93% over the last quarter.

QCSTRX - Stock Account Class R1 holds 2,027K shares representing 0.13% ownership of the company. In its prior filing, the firm reported owning 2,255K shares , representing a decrease of 11.27%. The firm decreased its portfolio allocation in AZNCF by 21.74% over the last quarter.

CIUEX - Six Circles International Unconstrained Equity Fund holds 1,568K shares representing 0.10% ownership of the company. In its prior filing, the firm reported owning 2,180K shares , representing a decrease of 38.99%. The firm decreased its portfolio allocation in AZNCF by 33.73% over the last quarter.

JAGLX - Janus Henderson Global Life Sciences Fund Class T holds 1,315K shares representing 0.08% ownership of the company. In its prior filing, the firm reported owning 1,292K shares , representing an increase of 1.70%. The firm increased its portfolio allocation in AZNCF by 3.54% over the last quarter.

TIIEX - TIAA-CREF International Equity Fund Institutional Class holds 904K shares representing 0.06% ownership of the company. In its prior filing, the firm reported owning 1,130K shares , representing a decrease of 24.96%. The firm decreased its portfolio allocation in AZNCF by 16.69% over the last quarter.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.